All three of Affinium Pharmaceuticals Inc.'s original Series A investors have returned for a $15 million follow-on financing. SV Life Sciences, Genesis Capital Partners and Forward Ventures are joined by new investor Ontario Emerging Technologies Fund in a financing round that will support completion of a Phase II trial of Affinium's oral antibiotic AFN-1252, and Phase I trials of an I.V. formulation of the same drug.